How Does Cannabis Affect the Body and Brain?
Cannabis has affects on both the brain and the body, making it a powerful treatment tool when used properly, but what are the affects and how can we tailor the use of cannabis to best suit treatment?

Cannabis has become a focal point of global interest, lauded for its therapeutic promise and increasingly accepted through legalization efforts in regions like North America and Europe. Its potential to alleviate conditions such as chronic pain, epilepsy, and anxiety has fueled both enthusiasm and debate. Yet, beneath the headlines, a critical question persists: how does cannabis truly affect the body and brain? From the euphoria of a recreational high to concerns about memory or mental health, cannabis’s influence is multifaceted, shaped by its chemical makeup, user biology, and consumption habits. Understanding these effects is vital as cannabis shifts from a controlled substance to a widely available tool for wellness and recreation.
Historically, cannabis has been used for millennia across cultures—for example, in ancient India as part of Ayurvedic remedies for pain and stress, or in the Middle East for its calming properties. By the 19th century, Western medicine embraced cannabis extracts for ailments like migraines and insomnia, only for prohibition to halt progress in the 20th century. Today, as legal barriers erode, scientific curiosity is surging, though decades of restriction have left gaps in our knowledge. This has led to a mix of excitement, skepticism, and misinformation that underscores the need for clarity.
At its core, cannabis’s effects hinge on two primary compounds: tetrahydrocannabinol (THC), the psychoactive driver of the "high," and cannabidiol (CBD), a non-intoxicating compound prized for its anti-inflammatory and anxiolytic properties. Beyond these, cannabis contains over 100 cannabinoids, plus terpenes and flavonoids, creating a complex interplay that varies with strain, dose, and delivery method. This article explores how cannabis engages the body’s endocannabinoid system, its immediate and prolonged impacts, and strategies for safe use, empowering readers to navigate its benefits and risks with confidence.
Cannabis and the Endocannabinoid System (ECS)
Cannabis exerts its effects by tapping into the endocannabinoid system (ECS), a sophisticated regulatory network discovered in the 1990s during THC research. The ECS governs a range of physiological processes, think mood stabilization, pain management, and immune response, making it a linchpin of bodily balance.
How the ECS Works
The ECS operates through three key components:
- Endocannabinoids: These are the body’s own cannabis-like molecules, such as anandamide (nicknamed the "bliss molecule" for its role in happiness) and 2 arachidonoylglycerol (2-AG). They’re produced on demand to fine-tune responses to stress or injury.
- Cannabinoid Receptors:
- CB1 receptors, abundant in the brain and central nervous system, influence memory, emotion, appetite, and motor skills.
- CB2 receptors, located mainly in immune cells and peripheral tissues, help regulate inflammation and pain.
- Enzymes: These break down endocannabinoids after use; e.g., fatty acid amide hydrolase (FAAH) degrades anandamide, ensuring the system resets.
Picture the ECS as a thermostat for homeostasis: it adjusts the body’s settings to maintain equilibrium. For instance, after a workout, endocannabinoids might soothe muscle inflammation or boost mood, a process so essential it’s shared across mammals and even some invertebrates (McPartland et al., 2006).
How Cannabis Influences the ECS
Cannabis introduces phytocannabinoids—plant-derived compounds—that mimic or modulate endocannabinoids:
- THC locks onto CB1 receptors like a key in a lock, replicating anandamide’s effects but with greater intensity. This binding sparks the psychoactive sensations; euphoria, time distortion, heightened senses, that define the cannabis experience. However, overuse can overstimulate CB1 receptors, disrupting normal signaling.
- CBD takes a subtler approach. It doesn’t bind strongly to CB1 or CB2 but enhances endocannabinoid activity by slowing anandamide breakdown. It also engages serotonin receptors (5-HT1A), contributing to its anti-anxiety effects (Blessing et al., 2015). Intriguingly, CBD can temper THC’s downsides, like paranoia, by modulating CB1 activity (Bhattacharyya et al., 2010).
The Entourage Effect
Cannabis’s impact isn’t just about THC or CBD—it’s a team effort. The entourage effect describes how cannabinoids, terpenes (aromatic compounds), and other molecules collaborate to shape outcomes. For example:
- Myrcene, earthy and sedative, amplifies THC’s relaxing properties, aiding sleep.
- Limonene, citrusy and uplifting, may ease anxiety and enhance mood.
- Pinene, with a pine-like scent, might sharpen focus and offset THC’s memory haze.
A 2011 study by Russo suggests this synergy makes whole-plant cannabis more effective than isolated compounds, a concept driving the popularity of full-spectrum products (Russo, 2011). Understanding this interplay can guide users toward strains tailored to their goals, whether pain relief or creative inspiration.
Short-Term Effects on the Body and Brain
Cannabis’s immediate effects are a rollercoaster, ranging from blissful calm to uneasy jitters, depending on strain potency, THC-CBD ratio, and how it’s consumed.
Effects on the Brain
- Memory and Cognition: THC tinkers with the hippocampus, the brain’s memory hub, impairing short-term recall. A 2016 study showed that infrequent users struggled to remember word lists after THC exposure, though tolerance builds with regular use (Curran et al., 2016). This can make multitasking or driving dicey.
- Attention and Focus: Low THC doses might ignite creativity, think of artists sketching wildly, but higher amounts cloud concentration and slow reflexes (Crean et al., 2011). A writer might pen a masterpiece at 5 mg but lose the plot at 20 mg.
- Mood and Anxiety: THC’s mood effects are a tightrope walk. Small doses often melt stress, but high-THC strains can spark anxiety or paranoia, especially in novices (Volkow et al., 2014). CBD, however, steadies the rope, reliably reducing anxiety across doses (Zuardi et al., 2017).
- Sensory Perception: THC amplifies senses; music vibrates deeper, food tastes richer, but it can warp time, stretching seconds into minutes, a quirk tied to CB1 activity in the cerebellum.
Consumption method shapes these effects. Smoking or vaping hits fast (within minutes), peaking sharply, while edibles creep in slowly (30–90 minutes) with a longer, gentler wave, sometimes catching users off-guard if they overdo it.
Effects on the Body
- Pain Modulation: THC and CBD team up with CB1 and CB2 receptors to dull pain signals. A 2018 review found cannabis eased chronic pain in 60% of studied cases, though relief varies by condition (Stockings et al., 2018).
- Appetite Stimulation: THC flips the hunger switch in the hypothalamus, unleashing the "munchies." This aids patients with appetite loss, like those on chemotherapy, but can challenge dieters (Kirkham, 2009).
- Cardiovascular Effects: THC spikes heart rate (up to 50 beats per minute) and dilates blood vessels, which might strain those with heart conditions (Mittleman et al., 2001). Red eyes? That’s vasodilation at work.
- Motor Coordination: By nudging the cerebellum, THC dulls balance and reaction time, raising accident risks; tripping over a curb or misjudging a turn (Hart et al., 2001).
These short-lived shifts highlight why timing and setting matter, using cannabis before a hike differs vastly from using it before bed.
Long-Term Effects and Mental Health**
Chronic cannabis use can leave lasting marks, particularly with heavy THC exposure, though CBD offers a counterbalance. Effects depend on frequency, age of first use, and genetic makeup.
Memory and Cognitive Function
- Structural Changes: Persistent THC use may shrink the hippocampus and amygdala, key players in memory and emotion. A 2012 study tied heavy teen use to an IQ drop of 6–8 points by adulthood, though critics argue lifestyle factors muddy the data (Meier et al., 2012).
- Neuroprotection: CBD flips the script, showing neuroprotective potential. Lab studies hint it may shield neurons from THC damage and even spur brain cell growth (Campos et al., 2016).
- Cognitive Flexibility: Long-term users often lag in tasks needing quick shifts, like solving puzzles under pressure, but abstinence can reverse much of this (Crean et al., 2011).
Mental Health Considerations
- Anxiety and Depression: Cannabis is a double-edged sword. CBD-rich strains soothe anxiety, while high-THC ones might amplify it, or spark apathy in depression-prone users (Crippa et al., 2009). A patient might find calm with a 1:1 strain but unease with a THC-heavy vape.
- Psychosis Risk: Heavy THC use, especially before brain maturity (around age 25), ups the odds of psychosis in those genetically at risk. A 2019 study linked daily high-potency use to a threefold psychosis increase (Di Forti et al., 2019).
- Addiction Potential: About 9% of users develop cannabis use disorder (CUD), jumping to 17% for teens. CBD, though, shows promise in easing withdrawal, offering a lifeline for quitting (Lopez-Quintero et al., 2011; Hurd et al., 2019).
Age matters; teen brains, still wiring, are more vulnerable than adult ones, pushing the case for delayed use.
Safe Use and Choosing Quality Products
Maximizing cannabis’s upside while dodging pitfalls starts with quality and caution.
Why Dispensary-Sourced Products Are the Best Choice
- Lab Testing for Purity: Licensed dispensaries test for nasties like mold, pesticides (e.g., myclobutanil), and heavy metals (e.g., lead). A 2020 study found 80% of street cannabis failed safety checks (Busse et al., 2020).
- Consistent Cannabinoid Profiles: Labels list exact THC and CBD levels; 15% THC, 5% CBD, ensuring predictable dosing.
- Regulated Manufacturing: Legal growers follow strict rules, minimizing risks like synthetic additives found in black-market carts.
- Avoiding Unregulated Products: Illicit weed might hide surprises, think fentanyl traces or inflated potency, making it a gamble.
Guidelines for Responsible Consumption
- Start Low, Go Slow: New users should try 2.5–5 mg THC or 10–20 mg CBD, waiting 2 hours for edibles to kick in.
- Balance THC with CBD: A 1:1 ratio softens the high while boosting relief, great for pain or sleep.
- Pick Safer Methods: Vaping or tinctures skip smoking’s tar and carcinogens; edibles avoid lungs entirely.
- Track and Tweak: Logging doses and reactions (e.g., “5 mg felt great, 10 mg made me foggy”) refines your sweet spot.
- Talk to Pros: Doctors or budtenders can flag drug interactions; THC amplifying sedatives, or tailor strains to needs.
Real-world tip: a beginner might vape 2 mg THC at a concert for fun but skip edibles until home, avoiding an unexpected marathon high.
Conclusion
Cannabis weaves a intricate tapestry of effects through the endocannabinoid system, offering relief and recreation alongside risks. Short-term, it can relax or rattle, depending on dose and delivery; long-term, it might reshape cognition or mental health, especially in youth. THC drives the highs and lows, while CBD steadies the ship, with terpenes adding flavor to the mix. By choosing lab-tested, dispensary-sourced cannabis and pacing consumption, users can harness its potential, be it for pain, stress, or curiosity, while sidestepping pitfalls. As science unravels cannabis’s mysteries, staying informed remains the cornerstone of smart use.
Authorship and Transparency
This article is opinion, written and medically reviewed by Hytiva's Chief Science Officer, Robert Seik, PharmD, FMNM based on emerging medical research. It's contents may be updated periodically to reflect new research from Hytiva and others, as well as the changing perspectives of the medical community. Specific examples are examples, hypothetical, or names are changed for patient anonymity. While the contents of this article are medically reviewed, each individual is unique and readers should only make medical decisions with the advice and consultation of their doctor.
References
- Bhattacharyya, S., et al. (2010). Opposite effects of THC and CBD on brain function. Neuropsychopharmacology, 35(3), 764-774.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823358/ - Blessing, E. M., et al. (2015). CBD as a treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/ - Busse, F., et al. (2020). Contaminants in illicit cannabis. Journal of Toxicology, 2020, 1-10.
https://www.hindawi.com/journals/jt/2020/6895421/ - Campos, A. C., et al. (2016). CBD and neuroprotection. Frontiers in Pharmacology, 7, Frontiers | Effects of Telephone Counseling Intervention by Pharmacists (TelCIP) on Medication Adherence; Results of a Cluster Randomized Trial
- Crean, R. D., et al.(2011). Cognitive effects of cannabis. Journal of Addiction Medicine, 5(1),1-8. (Manuscript linked as Published article requires subscription)
https://www.researchgate.net/publication/49818148_Cognitive_Effects_of_Cannabis_A_Reviewp - Crippa, J. A., et al. (2009). Cannabis and anxiety. Human Psychopharmacology, 24(7), 515-523. (Manuscript linked as Published article requires subscription)
https://www.researchgate.net/publication/26771545_Cannabis_and_anxiety_A_critical_review_of_the_evidence - Curran, H. V., et al. (2016). Cognitive effects of THC. Psychopharmacology, 187(1), 38-50. (Manuscript linked as Published article requires subscription)
https://www.researchgate.net/publication/11089709_Cognitive_and_subjective_dose-response_effects_of_acute_oral_D9-tetrahydrocannabinol_THC_in_infrequent_cannabis_users - Di Forti, M., et al. (2019). High-potency cannabis and psychosis. The Lancet Psychiatry, 6(5), 427-436. (Manuscript linked as Published article requires subscription) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study - The Lancet Psychiatry
- Hart, C. L., et al. (2001). Neurophysiological effects of smoked marijuana. Pharmacology Biochemistry and Behavior, 70(2-3), 299-309. (Requires Registration)
https://www.researchgate.net/publication/11633301_Neurophysiological_and_subjective_effects_of_smoked_marijuana_in_frequent_users - Hurd, Y. L., et al. (2019). CBD for addiction. Neurotherapeutics, 12(4), 807-815. (Manuscript linked as Published article requires subscription)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815095/ - Kirkham, T. C. (2009). Cannabinoids and appetite. British Journal of Pharmacology, 156(1), 1-13.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697758/ - Lopez-Quintero, C., et al. (2011). Cannabis dependence rates. Drug and Alcohol Dependence, 115(1-2), 120-130.
https://www.researchgate.net/publication/49659772_Probability_and_predictors_of_transition_from_first_use_to_dependence_on_nicotine_alcohol_cannabis_and_cocaine_Results_of_the_National_Epidemiologic_Survey_on_Alcohol_and_Related_Conditions_NESARC - McPartland, J. M., et al. (2006). Evolutionary origins of the ECS. Gene, 370, 64-74. (Manuscript linked as Published article requires subscription)
https://www.sciencedirect.com/science/article/pii/S0378111905006536 - Meier, M. H., et al. (2012). Cannabis and cognitive decline. PNAS, 109(40), E2657-E2664. Persistent cannabis users show neuropsychological decline from childhood to midlife | PNAS
- Mittleman, M. A., et al. (2001). Cannabis and cardiovascular risk. Circulation, 103(23), 2805-2809. Triggering Myocardial Infarction by Marijuana | Circulation
- Murray, R. M., et al. (2017). Cannabis and psychosis. Schizophrenia Bulletin, 43(6), 1262-1269. Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States | Schizophrenia Bulletin | Oxford Academic
- Russo, E. B. (2008). Cannabinoids in pain management. Therapeutics and Clinical Risk Management, 4(1), 245-259.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/ - Russo, E. B. (2011). Taming THC: Cannabis synergy. British Journal of Pharmacology, 163(7), 1344-1364.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/ - Schreiner, A. M., & Dunn, M. E. (2012). Residual effects of cannabis on cognition. Experimental and Clinical Psychopharmacology, 20(5), 373-386. (Manuscript linked as Published article requires subscription)
https://www.researchgate.net/publication/224967432_Residual_effects_of_cannabis_use_on_neurocognitive_performance_after_prolonged_abstinence_A_meta-analysis - Stockings, E., et al. (2018). Cannabis for chronic pain. Pain, 159(10), 1929-1941. (Requires Registration)
https://journals.lww.com/pain/Fulltext/2018/10000/Cannabis_and_cannabinoids_for_the_treatment_of.7.aspx - Volkow, N. D., et al. (2014). Adverse health effects of marijuana. NEJM, 370(23), 2219-2227. Adverse Health Effects of Marijuana Use | New England Journal of Medicine
- Zuardi, A. W., et al. (2017). CBD and anxiety. Brazilian Journal of Psychiatry, 39(2), 139-144.
https://www.scielo.br/j/rbp/a/3sB8gL4Z4Wnq6wDqF6nq6pQ/?lang=en